|Articles|February 7, 2006

Market for Needle-Free Injection Devices and Safety Syringes to Shoot Up to $2.49 Billion by 2009

NEW YORK -- With continuing incidences of needlestick injuries in the worldwide healthcare environment and high consumer demand for syringe alternatives, the market for needle-free injection systems and safety syringes is soaring-with some sectors growing in excess of 20 percent annually, and should reach $2.49 billion by 2009, according to a new study from market research firm Kalorama Information, a division of MarketResearch.com, a leading provider of industry-specific market research reports.

Annual needlestick injuries in the U.S. alone average 600,000 to 1 million, and estimates indicate that as many as 80 percent of the incidents could be prevented with the use of needle-free devices and safety syringes.

Needle-free Injection Systems and Safety Syringes: The Market for Alternatives to Needle-based Delivery predicts that the exorbitant costs associated with needlesticks -- costing institutions over $3,000 per injury even when no infection occurs -- coupled with other factors, such as patient fear of needles and the resulting lack of compliance, are strong enough drivers to grow the market by a compounded annual rate of 11 percent over the next four years.

Whether the devices are insulin pens for diabetics or mono-dose vaccine injectors, developing newer and safer ways of administering a wide variety of drug therapies is here to stay, even if such devices do come with a higher price tag.

"Certainly the development, testing, regulatory approval, and eventual mass manufacturing of such devices is not cheap, yet the costs need to be continually weighed against the greater benefit to global health," notes Joseph Constance, the report's author. "With newer injectable drugs coming to market and incidences of diseases requiring injectables, such as diabetes, escalating worldwide, the need for safer devices will continue to grow the market."

Source: Kalorama Information

   


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERISS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.